Novavax's COVID vaccine was shown to be 90% effective at preventing new cases in a clinical trial but carried the possible risk of causing heart inflammation, particularly in young males, Food and Drug Administration staff said in a review posted online Friday.
Why it matters: The company is seeking FDA emergency use authorization for the shot, positioning it both as a booster for the vaccinated and an alternative first-line defense for people who have refused mRNA shots.
